Getting your Trinity Audio player ready...
Northfield Laboratories Inc. said it will expand late-stage testing of its blood substitute, PolyHeme, at the request of the U.S. Food and Drug Administration. The Evanston-based company said the FDA requested the expanded test based on problems with competing products. Baxter International Inc. suspended a European test of its oxygen-carrying blood substitute in June. Northfield said it won’t complete the expanded trials until late spring of 1999. It had been expected to file for FDA approval as early as the end of this year.
